Compare WYETH LTD with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ASTRAZENECA PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ASTRAZENECA PHARMA WYETH LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 27.7 93.4 29.7% View Chart
P/BV x 5.3 26.3 20.3% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ASTRAZENECA PHARMA
Mar-18
WYETH LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0441,278 81.7%   
Low Rs818883 92.7%   
Sales per share (Unadj.) Rs298.6228.4 130.7%  
Earnings per share (Unadj.) Rs57.210.4 552.3%  
Cash flow per share (Unadj.) Rs58.416.3 359.2%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.598.8 252.6%  
Shares outstanding (eoy) m22.7225.00 90.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.7 65.9%   
Avg P/E ratio x16.3104.2 15.6%  
P/CF ratio (eoy) x15.966.4 24.0%  
Price / Book Value ratio x3.710.9 34.1%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,15727,008 78.3%   
No. of employees `0000.51.4 36.3%   
Total wages/salary Rs m4001,535 26.1%   
Avg. sales/employee Rs Th13,787.44,210.9 327.4%   
Avg. wages/employee Rs Th813.01,132.2 71.8%   
Avg. net profit/employee Rs Th2,643.3191.1 1,383.4%   
INCOME DATA
Net Sales Rs m6,7835,710 118.8%  
Other income Rs m353123 287.8%   
Total revenues Rs m7,1365,833 122.3%   
Gross profit Rs m1,617463 349.4%  
Depreciation Rs m27147 18.0%   
Interest Rs m60-   
Profit before tax Rs m1,938438 442.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632179 353.4%   
Profit after tax Rs m1,301259 501.9%  
Gross profit margin %23.88.1 294.1%  
Effective tax rate %32.640.8 79.9%   
Net profit margin %19.24.5 422.5%  
BALANCE SHEET DATA
Current assets Rs m6,9843,209 217.6%   
Current liabilities Rs m2,0562,070 99.3%   
Net working cap to sales %72.620.0 364.0%  
Current ratio x3.41.6 219.1%  
Inventory Days Days9972 137.2%  
Debtors Days Days2435 68.6%  
Net fixed assets Rs m244790 30.9%   
Share capital Rs m22750 454.4%   
"Free" reserves Rs m5,4412,419 224.9%   
Net worth Rs m5,6682,469 229.5%   
Long term debt Rs m250-   
Total assets Rs m7,9014,605 171.6%  
Interest coverage x353.3NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 69.2%   
Return on assets %16.55.6 293.8%  
Return on equity %22.910.5 218.7%  
Return on capital %34.017.7 191.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m15300 5.1%   
Fx outflow Rs m2,6772,015 132.9%   
Net fx Rs m-2,662-1,715 155.2%   
CASH FLOW
From Operations Rs m92388 1,050.3%  
From Investments Rs m317-94 -338.6%  
From Financial Activity Rs m-481NA-  
Net Cashflow Rs m759-6 -13,317.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 75.0 68.1%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 7.2 15.7 45.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 9.1 334.1%  
Shareholders   21,978 12,856 171.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   GSK PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare WYETH LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DIVIS LABORATORIES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS